Literature DB >> 31209011

Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation.

Angélica de L Rodríguez López1, Myung-Ryul Lee2, Nathan B Wang2, Kaitlin K Dunn2, Hiram Sanchez3, Namrata Raman2, David R Andes3, David M Lynn4,2,5, Sean P Palecek4,2.   

Abstract

Candida albicans is an opportunistic fungal pathogen responsible for mucosal candidiasis and systemic candidemia in humans. Often, these infections are associated with the formation of drug-resistant biofilms on the surfaces of tissues or medical devices. Increased incidence of C. albicans resistance to current antifungals has heightened the need for new strategies to prevent or eliminate biofilm-related fungal infections. In prior studies, we designed 14-helical β-peptides to mimic the structural properties of natural antimicrobial α-peptides (AMPs) in an effort to develop active and selective antifungal compounds. These amphiphilic, cationic, helical β-peptides exhibited antifungal activity against planktonic C. albicans cells and inhibited biofilm formation in vitro and in vivo Recent studies have suggested the use of antivirulence agents in combination with antifungals. In this study, we investigated the use of compounds that target C. albicans polymorphism, such as 1-dodecanol, isoamyl alcohol, and farnesol, to attempt to improve β-peptide efficacy for preventing C. albicans biofilms. Isoamyl alcohol, which prevents hyphal formation, reduced the minimum biofilm prevention concentrations (MBPCs) of β-peptides by up to 128-fold. Combinations of isoamyl alcohol and antifungal β-peptides resulted in less than 10% hemolysis at the antifungal MBPCs. Overall, our results suggest potential benefits of combination therapies comprised of morphogenesis modulators and antifungal AMP peptidomimetics for preventing C. albicans biofilm formation.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Candida albicanszzm321990; antimicrobial peptide mimetic; biofilm; morphogenesis

Mesh:

Substances:

Year:  2019        PMID: 31209011      PMCID: PMC6709471          DOI: 10.1128/AAC.02653-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  62 in total

Review 1.  The metabolic basis of Candida albicans morphogenesis and quorum sensing.

Authors:  Ting-Li Han; Richard D Cannon; Silas G Villas-Bôas
Journal:  Fungal Genet Biol       Date:  2011-04-12       Impact factor: 3.495

Review 2.  Use of antimicrobial peptides against microbial biofilms: advantages and limits.

Authors:  Giovanna Batoni; Giuseppantonio Maisetta; Franca Lisa Brancatisano; Semih Esin; Mario Campa
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?

Authors:  Kim A Brogden
Journal:  Nat Rev Microbiol       Date:  2005-03       Impact factor: 60.633

Review 4.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.

Authors:  Robert E W Hancock; Hans-Georg Sahl
Journal:  Nat Biotechnol       Date:  2006-12       Impact factor: 54.908

Review 5.  The clinical importance of fungal biofilms.

Authors:  Gordon Ramage; Craig Williams
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

6.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

7.  Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis.

Authors:  Amber Davis-Hanna; Amy E Piispanen; Lubomira I Stateva; Deborah A Hogan
Journal:  Mol Microbiol       Date:  2008-01       Impact factor: 3.501

8.  In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.

Authors:  Aspasia Katragkou; Matthew McCarthy; Elizabeth L Alexander; Charalampos Antachopoulos; Joseph Meletiadis; Mary Ann Jabra-Rizk; Vidmantas Petraitis; Emmanuel Roilides; Thomas J Walsh
Journal:  J Antimicrob Chemother       Date:  2014-10-06       Impact factor: 5.790

Review 9.  Hidden killers: human fungal infections.

Authors:  Gordon D Brown; David W Denning; Neil A R Gow; Stuart M Levitz; Mihai G Netea; Theodore C White
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

10.  Antifungal Activity of 14-Helical β-Peptides against Planktonic Cells and Biofilms of Candida Species.

Authors:  Namrata Raman; Myung-Ryul Lee; David M Lynn; Sean P Palecek
Journal:  Pharmaceuticals (Basel)       Date:  2015-08-13
View more
  2 in total

1.  Streptomyces: Derived Active Extract Inhibits Candida albicans Biofilm Formation.

Authors:  Sheng-Qiang Yang; Hui-Jie Zhou; Li-Ping Teng; Hong Zeng
Journal:  Curr Microbiol       Date:  2022-09-25       Impact factor: 2.343

Review 2.  Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities.

Authors:  Xiaoyan Wu; Yaoyao Xia; Fang He; Congrui Zhu; Wenkai Ren
Journal:  Microbiome       Date:  2021-03-14       Impact factor: 14.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.